What the research found

This piece is a clinical perspective rather than a research report. The author, a physician, describes how she counsels patients on statin use, drawing on evidence that statins reduce LDL cholesterol and are associated with improved outcomes in patients with established coronary artery disease. She notes that the data do not support the common patient concern that statins cause dementia—in fact, the mechanisms that protect blood vessels appear to benefit brain health as well. She also notes that dietary supplements like berberine and omega-3s lack the evidence base that supports statin use in high-risk patients.

The core insight is that statin benefit scales with individual cardiovascular risk, which varies substantially between people based on age, genetics, lifestyle, hormonal status, and metabolic factors. The author emphasises that elevated cholesterol or the presence of coronary plaque does not indicate personal failure, but rather reflects biology that lifestyle alone may not fully override.

Why it matters for you

If you're tracking lipids and considering statins, this framing may help clarify your decision. Many MyKine users optimise diet, sleep, and exercise specifically to manage cholesterol and reduce cardiovascular risk. Those efforts matter—but for some people, they won't be sufficient. Genetics and age set a baseline that lifestyle can improve but not necessarily eliminate.

If you've had a coronary calcium scan or other imaging showing plaque, or if your LDL remains elevated despite disciplined nutrition and training, a statin may offer benefits that supplements won't. The author's point is direct: berberine and fish oil have a place in a protocol, but they operate on different evidence than statins do in secondary prevention (when disease is already present).

The psychological framing also matters. Taking medication when you've done everything "right" can feel like failure—particularly for health-optimisation minded people. Reconceptualising a statin as risk management rather than an admission of defeat may help you make a clearer decision aligned with your actual cardiovascular profile.

Caveats

  • Opinion-based, not evidence synthesis. This is a clinician's perspective on how to communicate risk, not a systematic review or clinical trial.
  • No effect sizes or outcome data provided. The author references "abundant medical literature" and "outcomes data" but does not cite specific trials, effect sizes, or absolute risk reductions.
  • Generalisation risk. The cases described are illustrative; individual risk varies widely and requires personalised assessment.
  • Supplement claims lack detail. The claim that berberine and omega-3s lack equivalent evidence is stated without reference; specific trial data would strengthen that comparison.